

IN THE CLAIMS:

Please amend claims 3, 15, 24, and 50 as follows:

3. (Currently and Previously Amended) A pharmaceutical composition for treating sexual dysfunction in a mammal comprising a therapeutically effective amount of a dopamine receptor agonist that exhibits activity for alleviating said sexual dysfunction in an aqueous formulation for intranasal delivery, wherein said pharmaceutical composition is intranasally effective to alleviate said sexual dysfunction without causing substantial intolerable adverse side effects in said mammal.

15. A pharmaceutical composition for treating male or female sexual dysfunction in a mammalian subject comprising a therapeutically effective amount of a dopamine receptor agonist that exhibits activity for alleviating said sexual dysfunction dispersed in an aqueous formulation for intranasal delivery comprising a buffer to maintain a pH of the formulation, a pharmaceutically acceptable thickening agent and a humectant, wherein said pharmaceutical composition is intranasally effective to alleviate said sexual dysfunction and does not cause substantial intolerable adverse side effects when administered to said mammal.

24. An intranasal dosage unit for treating impotency or erectile dysfunction in a mammal comprising an effective amount of a dopamine receptor agonist that exhibits activity for treating said impotency or erectile dysfunction in an aqueous formulation for intranasal delivery comprising a buffer, wherein said dosage unit does not cause substantial intolerable adverse side effects in said mammal and an erection is produced in said mammal within about 60 minutes of administering said dosage unit to a nasal mucosa of said mammal.

50. A pharmaceutical composition for treating male erectile dysfunction in a mammal comprising a therapeutically effective amount of a dopamine receptor agonist that exhibits activity for treating said male erectile dysfunction which has been dispersed in an aqueous formulation for intranasal delivery comprising a stabilizing agent to improve stability of said dopamine receptor agonist in the formulation.